☆ 4.6 Article

Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination

NPJ VACCINES (2022)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Wilfredo F. Garcia-Beltran et al.

Summary: Recent surveillance has identified the emergence of the SARS-CoV-2 Omicron variant, which carries up to 36 mutations in the spike protein and has the potential to evade vaccine-induced immunity. This study found that individuals vaccinated with mRNA vaccines exhibited strong neutralization of the Omicron variant, while most vaccinees had weak neutralization. The study also revealed that the Omicron variant infects more efficiently than other tested variants.

CELL (2022)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Roos S. G. Sablerolles et al.

Summary: This study investigated the immunogenicity and reactogenicity of a homologous or heterologous booster in healthcare workers who had received a single-shot Ad26.COV2.S vaccine. The results showed that booster vaccinations increased the levels of S-specific binding antibodies, neutralizing antibodies, and T-cell responses compared to a single Ad26.COV2.S vaccination. Boosters containing mRNA-based vaccines induced significantly higher levels of binding antibodies than homologous boosters. The mRNA-1273 booster was the most immunogenic but had higher reactogenicity compared to the BNT162b2 and Ad26.COV2.S boosters. Local and systemic reactions were generally mild to moderate in the first 2 days after booster administration.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Immunology

Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation

Maria G. Byazrova et al.

Summary: The development of effective vaccines against SARS-CoV-2 is crucial. The study found that Sputnik V vaccination can result in robust B cell immunity, which is influenced by the individuals' history of SARS-CoV-2 infection. The research shows that B memory cell responses to Sputnik V play a significant role in neutralizing the virus and may provide insights into future responses against emerging variants.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant

Kevin K. Arien et al.

Summary: This study reports the levels of neutralizing antibodies against Wuhan, Delta, and Omicron variants in different groups of individuals. The findings support the use of booster vaccines to prevent infection and disease caused by the Omicron variant.

NPJ VACCINES (2022)

Add to Collection

Article Immunology

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations

Juan Manuel Carreno et al.

Summary: This study found differential induction of anti-PEG antibodies by mRNA-1273 and BNT162b2 vaccines. Although mRNA-1273 vaccine elicited increased reactivity to PEG, there was no obvious association between PEG antibodies and adverse reactions.

VACCINE (2022)

Add to Collection

Article Virology

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine

Kerri Basile et al.

Summary: The Omicron variant of SARS-CoV-2, declared as the fifth variant of concern by the World Health Organization, has multiple spike protein mutations that raise concerns about immune evasion. Research shows that sera from individuals who received two doses of the Pfizer-BioNTech BNT162b2 vaccine have limited neutralizing ability against SARS-CoV-2, but a third dose can boost neutralizing antibody titres. However, even with the boost, neutralizing antibody titres for Omicron are four times lower compared to the A.2.2 lineage of SARS-CoV-2.

VIRUSES-BASEL (2022)

Add to Collection

Review Immunology

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Jerome Custers et al.

Summary: This article reviews the safety and efficacy of Ad26 vector-based vaccines in clinical trials, showing good tolerability and immunogenicity in multiple studies. New developments in Ad26-based vaccines, including a COVID-19 vaccine currently in phase 3 clinical evaluation, are promising for vaccine development.

VACCINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Article Cell Biology

Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern

Andrey A. Gorchakov et al.

Summary: In the absence of approved small-molecule drugs targeting the virus, broadening the repertoire of potent SARS-CoV-2-neutralizing antibodies is crucial. This study isolated 23 RBD-specific human monoclonal antibodies with strong virus-neutralizing activity, including four categorized as ultrapotent. These antibodies retain activity against various SARS-CoV-2 variants and could effectively prevent viral replication and lung pathology.

CELL DISCOVERY (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action

Franz X. Heinz et al.

Summary: COVID-19 vaccines have been rapidly developed using different technologies, including mRNA, adenoviral vectors, and inactivated vaccines. They all rely on the viral spike protein of SARS-CoV-2 to induce neutralizing antibodies, but the presentation of this key antigen to the immune system varies between different vaccine categories.

NPJ VACCINES (2021)

Add to Collection

Article Health Care Sciences & Services

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults

Amir Tukhvatulin et al.

Summary: A study conducted in Russia indicates that the newly developed single-dose vaccine Sputnik Light demonstrates good safety and immunogenicity against COVID-19, significantly boosting antibody levels and eliciting positive responses at the immune cell level.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Immunology

Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19

Maria Byazrova et al.

Summary: The study analyzed the generation of plasmablasts and RBD-specific memory B cells in patients during the acute phase of COVID-19. The activation and proliferation of Bmem cells were induced which led to the generation of plasmablast phenotypic cells and RBD-specific ASCs. Additionally, it was found that SARS-CoV-2-specific Bmem cells are generated during the acute phase of COVID-19, providing a basis for further studies on the longevity of SARS-CoV-2-specific B-cell memory.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

Add to Collection

Article Immunology

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

Rinke Bos et al.

NPJ VACCINES (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

A review of Dengvaxia?: development to deployment

Stephen J. Thomas et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)

Add to Collection

Article Multidisciplinary Sciences

Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge

Freek Cox et al.

PLOS ONE (2018)

Add to Collection

Article Immunology

Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy

Ekramy E. Sayedahmed et al.

VACCINE (2018)

Add to Collection

Review Immunology

Adenovirus-vectored Ebola vaccines

Sarah C. Gilbert

EXPERT REVIEW OF VACCINES (2015)

Add to Collection

Review Biotechnology & Applied Microbiology

Pre-existing immunity against Ad vectors Humoral, cellular, and innate response, what's important?

Hugues Fausther-Bovendo et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)

Add to Collection

Article Immunology

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

Lindsey R. Baden et al.

JOURNAL OF INFECTIOUS DISEASES (2013)

Add to Collection

Article Immunology

Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)

Dan H. Barouch et al.

JOURNAL OF INFECTIOUS DISEASES (2013)

Add to Collection

Article Medicine, General & Internal

Association between the 2008-09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring-Summer 2009: Four Observational Studies from Canada

Danuta M. Skowronski et al.

PLOS MEDICINE (2010)

Add to Collection

Article Immunology

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

Andrew T. Catanzaro et al.

JOURNAL OF INFECTIOUS DISEASES (2006)

Add to Collection

Article Virology

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

S Santra et al.

JOURNAL OF VIROLOGY (2005)

Add to Collection

Review Medicine, Research & Experimental

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

JW Shiver et al.

ANNUAL REVIEW OF MEDICINE (2004)

Add to Collection

Article Immunology

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

DH Barouch et al.

JOURNAL OF IMMUNOLOGY (2004)

Add to Collection

Article Virology

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene

DR Casimiro et al.

JOURNAL OF VIROLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.